Beyond the Daily Pill
The era of daily pill fatigue is ending. The future of HIV prevention is moving toward less frequent, highly potent therapies that promise to revolutionize adherence and efficacy.
Cabotegravir and Lenacapavir
Cabotegravir is a long-acting injectable PrEP administered every two months, showing remarkable success in preventing transmission. Even more groundbreaking is Lenacapavir, a 6-monthly injection that showed 100% efficacy in recent HPTN083/084 trials. These treatments offer immense hope for populations struggling with daily adherence.
The Promise of Vaccines and bnAbs
Following the rapid success of COVID-19 mRNA vaccines, the medical community is pivoting this technology toward HIV. The challenge lies in HIV's rapid mutation and extreme genetic diversity. However, trials involving broadly neutralizing antibodies (bnAbs) are showing potential in keeping the virus suppressed without daily ART.
The ImmunityBio N-803 Trials
Innovations like the ImmunityBio N-803 combined with BCG are currently in trials to investigate if they can flush the virus out of latently infected cells. IAVI partnerships in India are also working hard to ensure that once a vaccine is viable, it will be accessible in the developing world.
The "Functional Cure"
Can HIV be cured? We are closer than ever. CRISPR gene-editing technology is being explored to literally cut HIV DNA out of infected human cells. We have already seen unique cases like the Berlin Patient and the London Patient, who were functionally cured through stem cell transplants. While not a scalable treatment yet, these cases prove that a cure is biologically possible. The next 10 years bring realistic, science-backed optimism.
